• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Biocept to Report 2021 Fourth Quarter and Full Year Financial Results on March 31, 2022

    3/18/22 8:00:00 AM ET
    $BIOC
    Medical Specialities
    Health Care
    Get the next $BIOC alert in real time by email

    Biocept, Inc. (NASDAQ:BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange Commission (SEC) on Thursday, March 31, 2022. Management will not hold an investment community conference call with the reporting of 2021 fourth quarter and full year financial results.

    Biocept plans to announce financial results for the three months ended March 30, 2022 in mid-May 2022. Management plans to hold an investment community conference call in conjunction with reporting first quarter 2022 financial results in which it plans to unveil the company's rationalized business strategy including near-term milestones.

    About Biocept

    Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220316006140/en/

    Get the next $BIOC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Walsh Robert

      3 - BIOCEPT INC (0001044378) (Issuer)

      6/20/23 7:09:58 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Dao-Haddock Quyen Thi

      4 - BIOCEPT INC (0001044378) (Issuer)

      11/18/22 8:26:29 PM ET
      $BIOC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Dao-Haddock Quyen Thi

      3 - BIOCEPT INC (0001044378) (Issuer)

      11/18/22 8:22:42 PM ET
      $BIOC
      Medical Specialities
      Health Care

    $BIOC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. "Completing enrollment in this first phase of our FORESEE trial, and doing so ahead of our inte

      9/21/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care
    • Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics

      Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (NASDAQ:PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal metastases (LM), which is cancer in the membranes that surround the brain and spinal cord. CNSide is Biocept's proprietary cerebrospinal fluid (CSF)-based tumor cell capture and enumeration p

      9/8/23 8:00:00 AM ET
      $BIOC
      $PSTV
      Medical Specialities
      Health Care
      Medical/Dental Instruments
    • Biocept to Participate in the H.C. Wainwright Global Investment Conference

      Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company's website beginning Monday, September 11 at 7:00 a.m. Eastern time. Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel. About Biocept

      9/5/23 8:00:00 AM ET
      $BIOC
      Medical Specialities
      Health Care